Paul A. Friedman, M.D. was the Chief Executive Officer and a Director of Incyte Corporation from November 2001 and also its President from May 2004 until his retirement in January 2014. Dr. Friedman has been a Director of Durata Therapeutics, Inc. since May 16, 2013. He has been a Non Executive Director at Gliknik, Inc. since February 25, 2013 and a Director at Incyte Corporation since November 2001 and Auxilium Pharmaceuticals Inc. since June 2010. From 1998 until October 2001, Dr. Friedman served as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), from 1994 to 1998 he served as President of Research and Development of The DuPont Merck Pharmaceutical Company, and from 1991 to 1994 he served as Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an Associate Professor of Medicine and Pharmacology at Harvard Medical School. Dr. Friedman is a Diplomate of the American Board of Internal Medicine and a Member of the American Society of Clinical Investigation. He received his A.B. in Biology from Princeton University and his M.D. from Harvard Medical School.